Abcuro valuation, funding and investors

Abcuro works in biopharmaceutical research and development, based in Newton, United States. Founded in 2015, it has about 36 employees.

Pharmaceutical Products Series D

VALUATION · TODAY

$826M −7% after Series D

Range $542M – $1.27B · Grade B

TODAY

+12 MO

$1.00B

$2.00B

$3.00B

$4.00B

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series A $42.0M

Series B $155M

Series C $200M

Series D $66.0M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY36 employees

−36%6m growth

−33%1y growth

−14%2y growth

Data from Jan 2021

TODAY

Predicted in 1 yr $770M −7% vs today

Predicted next raise $118M if a round comes

Winding-down probability 97%

Last round: Series D · $66.0M · Aug 2026
Valuation at last round: $825M · implied
Headcount: 36 · shrinking
Grade: B
Founded: 2015

How VCMC values companies →

Abcuro valuation today

VCMC values Abcuro at $826M today, with a range of $542M to $1.3B and a grade of B. The valuation starts from its last funding round, a Series D round in Aug 2026.

Valuation by date (147 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Abcuro: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2015	$5.25M	$1.91M – $14.4M	$5.51M (+5%)	before first round	–	unknown	D	0%
1 Feb 2015	$5.28M	$1.92M – $14.5M	$5.53M (+5%)	before first round	–	unknown	D	0%
1 Mar 2015	$5.29M	$1.93M – $14.5M	$5.55M (+5%)	before first round	–	unknown	D	0%
1 Apr 2015	$5.32M	$1.93M – $14.6M	$5.57M (+5%)	before first round	–	unknown	D	0%
1 May 2015	$5.34M	$1.94M – $14.7M	$5.59M (+5%)	before first round	–	unknown	D	0%
1 Jun 2015	$5.36M	$1.95M – $14.7M	$5.61M (+5%)	before first round	–	unknown	D	0%
1 Jul 2015	$5.38M	$1.96M – $14.8M	$5.64M (+5%)	before first round	–	unknown	D	0%
1 Aug 2015	$5.40M	$1.97M – $14.8M	$5.78M (+7%)	before first round	–	unknown	D	0%
1 Sep 2015	$5.42M	$1.97M – $14.9M	$5.94M (+10%)	before first round	–	unknown	D	0%
1 Oct 2015	$5.44M	$1.98M – $14.9M	$6.09M (+12%)	before first round	–	unknown	D	0%
1 Nov 2015	$5.46M	$1.99M – $15.0M	$6.26M (+15%)	before first round	–	unknown	D	0%
1 Dec 2015	$5.48M	$2.00M – $15.1M	$6.42M (+17%)	before first round	–	unknown	D	0%
1 Jan 2016	$5.51M	$2.00M – $15.1M	$6.60M (+20%)	before first round	–	unknown	D	0%
1 Feb 2016	$5.53M	$2.01M – $15.2M	$6.78M (+23%)	before first round	–	unknown	D	0%
1 Mar 2016	$5.55M	$2.02M – $15.2M	$6.95M (+25%)	before first round	–	unknown	D	0%
1 Apr 2016	$5.57M	$2.03M – $15.3M	$7.14M (+28%)	before first round	–	unknown	D	0%
1 May 2016	$5.59M	$2.04M – $15.4M	$7.33M (+31%)	before first round	–	unknown	D	0%
1 Jun 2016	$5.61M	$2.04M – $15.4M	$7.53M (+34%)	before first round	–	unknown	D	0%
1 Jul 2016	$5.64M	$2.05M – $15.5M	$7.72M (+37%)	before first round	–	unknown	D	0%
1 Aug 2016	$5.79M	$2.11M – $15.9M	$7.93M (+37%)	before first round	–	unknown	D	0%
1 Sep 2016	$5.94M	$2.16M – $16.3M	$8.15M (+37%)	before first round	–	unknown	D	0%
1 Oct 2016	$6.10M	$2.22M – $16.8M	$8.36M (+37%)	before first round	–	unknown	D	0%
1 Nov 2016	$6.26M	$2.28M – $17.2M	$8.59M (+37%)	before first round	–	unknown	D	0%
1 Dec 2016	$6.43M	$2.34M – $17.7M	$8.81M (+37%)	before first round	–	unknown	D	0%
1 Jan 2017	$6.60M	$2.40M – $18.1M	$9.05M (+37%)	before first round	–	unknown	D	0%
1 Feb 2017	$6.78M	$2.47M – $18.6M	$9.29M (+37%)	before first round	–	unknown	D	0%
1 Mar 2017	$6.94M	$2.53M – $19.1M	$9.52M (+37%)	before first round	–	unknown	D	0%
1 Apr 2017	$7.13M	$2.60M – $19.6M	$9.78M (+37%)	before first round	–	unknown	D	0%
1 May 2017	$7.32M	$2.67M – $20.1M	$10.0M (+37%)	before first round	–	unknown	D	0%
1 Jun 2017	$7.52M	$2.74M – $20.7M	$10.3M (+37%)	before first round	–	unknown	D	0%
1 Jul 2017	$7.72M	$2.81M – $21.2M	$10.6M (+37%)	before first round	–	unknown	D	0%
1 Aug 2017	$7.93M	$2.89M – $21.8M	$10.9M (+37%)	before first round	–	unknown	D	0%
1 Sep 2017	$8.14M	$2.96M – $22.4M	$11.2M (+37%)	before first round	–	unknown	D	0%
1 Oct 2017	$8.36M	$3.04M – $23.0M	$11.5M (+37%)	before first round	–	unknown	D	0%
1 Nov 2017	$8.58M	$3.12M – $23.6M	$11.8M (+37%)	before first round	–	unknown	D	0%
1 Dec 2017	$8.81M	$3.21M – $24.2M	$12.1M (+37%)	before first round	–	unknown	D	0%
1 Jan 2018	$9.05M	$3.29M – $24.9M	$12.4M (+37%)	before first round	–	unknown	D	0%
1 Feb 2018	$9.29M	$3.38M – $25.5M	$12.7M (+37%)	before first round	–	unknown	D	0%
1 Mar 2018	$9.52M	$3.47M – $26.2M	$13.1M (+37%)	before first round	–	unknown	D	0%
1 Apr 2018	$9.78M	$3.56M – $26.9M	$13.4M (+37%)	before first round	–	unknown	D	0%
1 May 2018	$10.0M	$3.65M – $27.6M	$13.8M (+37%)	before first round	–	unknown	D	0%
1 Jun 2018	$10.3M	$3.75M – $28.3M	$14.1M (+37%)	before first round	–	unknown	D	0%
1 Jul 2018	$10.6M	$3.85M – $29.1M	$14.5M (+37%)	before first round	–	unknown	D	0%
1 Aug 2018	$10.9M	$3.96M – $29.9M	$14.7M (+35%)	before first round	–	unknown	D	0%
1 Sep 2018	$11.2M	$4.06M – $30.7M	$14.8M (+32%)	before first round	–	unknown	D	0%
1 Oct 2018	$11.5M	$4.17M – $31.5M	$14.9M (+30%)	before first round	–	unknown	D	0%
1 Nov 2018	$11.8M	$4.28M – $32.3M	$15.1M (+28%)	before first round	–	unknown	D	0%
1 Dec 2018	$12.1M	$4.40M – $33.2M	$15.2M (+26%)	before first round	–	unknown	D	0%
1 Jan 2019	$12.4M	$4.52M – $34.1M	$15.3M (+24%)	before first round	–	unknown	D	0%
1 Feb 2019	$12.7M	$4.64M – $35.0M	$15.5M (+21%)	before first round	–	unknown	D	0%
1 Mar 2019	$13.1M	$4.75M – $35.9M	$15.6M (+19%)	before first round	–	unknown	D	0%
1 Apr 2019	$13.4M	$4.88M – $36.8M	$15.7M (+17%)	before first round	–	unknown	D	0%
1 May 2019	$13.8M	$5.01M – $37.8M	$15.9M (+15%)	before first round	–	unknown	D	0%
1 Jun 2019	$14.1M	$5.15M – $38.8M	$16.0M (+13%)	before first round	–	unknown	D	0%
1 Jul 2019	$14.5M	$5.28M – $39.8M	$16.2M (+11%)	before first round	–	unknown	D	0%
1 Aug 2019	$14.7M	$5.33M – $40.2M	$16.3M (+11%)	before first round	–	unknown	D	0%
1 Sep 2019	$14.8M	$5.38M – $40.6M	$16.5M (+11%)	before first round	–	unknown	D	0%
1 Oct 2019	$14.9M	$5.43M – $41.0M	$16.6M (+11%)	before first round	–	unknown	D	0%
1 Nov 2019	$15.1M	$5.48M – $41.4M	$16.8M (+11%)	before first round	–	unknown	D	0%
1 Dec 2019	$15.2M	$5.53M – $41.7M	$16.9M (+11%)	before first round	–	unknown	D	0%
1 Jan 2020	$15.3M	$5.58M – $42.1M	$17.1M (+11%)	before first round	–	unknown	D	0%
1 Feb 2020	$15.5M	$5.63M – $42.5M	$17.2M (+11%)	before first round	–	unknown	D	0%
1 Mar 2020	$15.6M	$5.68M – $42.9M	$17.4M (+11%)	before first round	–	unknown	D	0%
1 Apr 2020	$15.7M	$5.73M – $43.3M	$17.5M (+11%)	before first round	–	unknown	D	0%
1 May 2020	$15.9M	$5.78M – $43.6M	$17.7M (+11%)	before first round	–	unknown	D	0%
1 Jun 2020	$16.0M	$5.84M – $44.0M	$17.9M (+11%)	before first round	–	unknown	D	0%
1 Jul 2020	$16.2M	$5.89M – $44.4M	$18.0M (+11%)	before first round	–	unknown	D	0%
1 Aug 2020	$16.3M	$5.94M – $44.8M	$18.2M (+11%)	before first round	–	unknown	D	0%
1 Sep 2020	$16.5M	$6.00M – $45.2M	$18.3M (+11%)	before first round	–	unknown	D	0%
1 Oct 2020	$16.6M	$6.05M – $45.6M	$18.5M (+11%)	before first round	–	unknown	D	0%
1 Nov 2020	$16.8M	$6.11M – $46.1M	$18.7M (+11%)	before first round	–	unknown	D	0%
1 Dec 2020	$16.9M	$6.16M – $46.5M	$18.8M (+11%)	before first round	–	unknown	D	0%
1 Jan 2021	$14.6M	$5.31M – $40.0M	$12.8M (-12%)	before first round	6	unknown	D	0%
8 Jan 2021	$234M	$153M – $639M	$420M (+80%)	after a round	6	unknown	C	0%
1 Feb 2021	$243M	$153M – $639M	$420M (+73%)	after a round	6	unknown	C	0%
1 Mar 2021	$254M	$153M – $639M	$420M (+65%)	after a round	6	unknown	C	0%
1 Apr 2021	$267M	$153M – $639M	$420M (+57%)	after a round	6	unknown	C	0%
1 May 2021	$280M	$153M – $639M	$420M (+50%)	after a round	6	unknown	C	0%
1 Jun 2021	$295M	$153M – $639M	$420M (+43%)	after a round	6	unknown	C	0%
1 Jul 2021	$309M	$153M – $639M	$420M (+36%)	after a round	6	unknown	C	0%
1 Aug 2021	$325M	$153M – $639M	$420M (+29%)	after a round	6	unknown	C	0%
1 Sep 2021	$342M	$153M – $639M	$420M (+23%)	after a round	6	unknown	C	0%
1 Oct 2021	$359M	$153M – $639M	$420M (+17%)	after a round	6	unknown	C	0%
1 Nov 2021	$377M	$153M – $639M	$420M (+11%)	after a round	6	unknown	C	0%
1 Dec 2021	$396M	$153M – $639M	$420M (+6%)	after a round	6	unknown	C	0%
1 Jan 2022	$416M	$153M – $639M	$420M (+1%)	after a round	6	unknown	C	0%
1 Feb 2022	$420M	$147M – $639M	$420M (0%)	after a round	6	unknown	C	0%
1 Mar 2022	$420M	$141M – $639M	$420M (0%)	after a round	6	unknown	C	0%
1 Apr 2022	$570M	$216M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 May 2022	$570M	$219M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 Jun 2022	$570M	$222M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 Jul 2022	$570M	$225M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 Aug 2022	$570M	$229M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 Sep 2022	$570M	$232M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 Oct 2022	$570M	$235M – $867M	$570M (0%)	after a round	24	growing	C	0%
1 Nov 2022	$570M	$128M – $867M	$570M (0%)	after a round	24	unknown	C	0%
1 Dec 2022	$570M	$121M – $867M	$570M (0%)	after a round	24	unknown	C	0%
1 Jan 2023	$598M	$196M – $911M	$598M (0%)	after a round	30	up	C	0%
1 Feb 2023	$598M	$149M – $911M	$597M (0%)	after a round	30	up	C	0%
1 Mar 2023	$598M	$145M – $911M	$596M (0%)	after a round	30	up	C	0%
1 Apr 2023	$598M	$140M – $911M	$595M (-1%)	after a round	30	up	C	0%
1 May 2023	$598M	$136M – $911M	$594M (-1%)	after a round	30	up	C	0%
1 Jun 2023	$598M	$132M – $911M	$592M (-1%)	after a round	30	up	C	0%
1 Jul 2023	$598M	$128M – $911M	$591M (-1%)	after a round	30	up	C	0%
1 Aug 2023	$598M	$124M – $911M	$590M (-1%)	after a round	30	up	C	0%
18 Aug 2023	$1.1B	$749M – $2.3B	$1.6B (+50%)	after a round	30	up	B	0%
1 Sep 2023	$1.1B	$749M – $2.3B	$1.6B (+48%)	after a round	30	up	B	0%
1 Oct 2023	$1.1B	$749M – $2.3B	$1.6B (+43%)	after a round	32	up	B	0%
1 Nov 2023	$1.2B	$749M – $2.3B	$1.6B (+38%)	after a round	32	flat	B	0%
1 Dec 2023	$1.2B	$749M – $2.3B	$1.6B (+33%)	after a round	32	flat	B	0%
1 Jan 2024	$1.2B	$749M – $2.3B	$1.6B (+29%)	after a round	32	flat	B	0%
1 Feb 2024	$1.3B	$749M – $2.3B	$1.6B (+24%)	after a round	32	flat	B	0%
1 Mar 2024	$1.3B	$774M – $2.3B	$1.6B (+22%)	after a round	37	up	B	0%
1 Apr 2024	$1.4B	$774M – $2.3B	$1.6B (+18%)	after a round	37	up	B	0%
1 May 2024	$1.4B	$774M – $2.3B	$1.6B (+14%)	after a round	37	up	B	0%
1 Jun 2024	$1.5B	$774M – $2.3B	$1.6B (+10%)	after a round	37	up	B	0%
1 Jul 2024	$1.6B	$774M – $2.3B	$1.6B (+6%)	after a round	37	up	B	0%
1 Aug 2024	$1.7B	$796M – $2.4B	$1.7B (+2%)	after a round	42	up	B	0%
1 Sep 2024	$1.7B	$793M – $2.4B	$1.7B (0%)	after a round	42	up	B	0%
1 Oct 2024	$1.7B	$789M – $2.4B	$1.7B (0%)	after a round	42	up	B	0%
1 Nov 2024	$1.7B	$788M – $2.4B	$1.7B (0%)	after a round	43	up	B	0%
1 Dec 2024	$1.7B	$784M – $2.4B	$1.7B (0%)	after a round	43	up	B	0%
1 Jan 2025	$1.7B	$780M – $2.4B	$1.7B (0%)	after a round	43	up	B	0%
1 Feb 2025	$1.7B	$775M – $2.4B	$1.7B (0%)	after a round	43	up	B	0%
13 Feb 2025	$1.8B	$1.3B – $3.3B	$2.3B (+30%)	after a round	43	up	B	0%
1 Mar 2025	$1.8B	$1.3B – $3.3B	$2.3B (+28%)	after a round	43	up	B	0%
1 Apr 2025	$1.9B	$1.3B – $3.3B	$2.3B (+26%)	after a round	43	up	B	0%
1 May 2025	$1.9B	$1.3B – $3.3B	$2.3B (+23%)	after a round	43	up	B	0%
1 Jun 2025	$1.9B	$1.3B – $3.3B	$2.3B (+20%)	after a round	43	up	B	0%
1 Jul 2025	$2.0B	$1.3B – $3.3B	$2.3B (+18%)	after a round	43	up	B	0%
1 Aug 2025	$2.1B	$1.3B – $3.5B	$2.4B (+18%)	after a round	54	growing	B	0%
1 Sep 2025	$2.1B	$1.3B – $3.5B	$2.4B (+15%)	after a round	54	growing	B	0%
1 Oct 2025	$2.2B	$1.3B – $3.5B	$2.4B (+12%)	after a round	54	up	B	0%
1 Nov 2025	$2.2B	$1.3B – $3.5B	$2.5B (+9%)	after a round	55	up	B	0%
1 Dec 2025	$2.3B	$1.3B – $3.5B	$2.5B (+7%)	after a round	55	up	B	0%
1 Jan 2026	$2.4B	$1.3B – $3.5B	$2.5B (+4%)	after a round	55	up	B	0%
1 Feb 2026	$2.4B	$1.3B – $3.5B	$2.5B (+1%)	after a round	55	up	B	0%
1 Mar 2026	$2.5B	$1.3B – $3.5B	$2.5B (0%)	after a round	56	up	B	0%
1 Apr 2026	$2.5B	$1.3B – $3.5B	$2.5B (0%)	after a round	56	up	B	0%
1 May 2026	$2.3B	$1.1B – $3.3B	$2.3B (0%)	after a round	42	flat	B	0%
1 Jun 2026	$1.7B	$1.0B – $2.6B	$1.2B (-26%)	after a round	42	down	B	97%
1 Jul 2026	$1.6B	$998M – $2.7B	$1.2B (-26%)	after a round	42	down	B	97%
1 Aug 2026	$1.6B	$949M – $2.7B	$1.2B (-26%)	after a round	42	down	B	97%
19 Aug 2026	$825M	$542M – $1.3B	$831M (+1%)	after a round	42	down	B	97%
1 Sep 2026	$825M	$542M – $1.3B	$823M (0%)	after a round	42	down	B	97%
1 Oct 2026	$826M	$542M – $1.3B	$790M (-4%)	after a round	36	shrinking	B	97%
24 Oct 2026	$826M	$542M – $1.3B	$770M (-7%)	after a round	36	shrinking	B	97%

Key facts about Abcuro

Founded: 2015
Headquarters: Newton, United States
Employees: about 36 -33% in a year
Total raised: $463M
Funding rounds: 4
Last round: Series D Aug 2026

Abcuro was founded in 2015 by Steven A. Greenberg.

Abcuro funding history

Abcuro has 4 funding rounds on record, from Jan 2021 to Aug 2026, $463M in total. None disclosed a valuation.

Series D 18 Aug 2026
Led by New Leaf Venture Partners; with abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital, Pontifax Venture Capital, Sanofi Ventures, Foresite Capital, New Enterprise Associates, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Rock Springs Capital. Individuals: Nancy Chang, Shang Bay.
Sources: abcuro.com, abcuro.com, citybiz.co and 2 more
$66M
Series C 12 Feb 2025
Led by New Enterprise Associates; with Foresite Capital.
Sources: shangbaycapital.com, synapse-patsnap-com.libproxy1.nus.edu.sg, abcuro.com
$200M
Series B 17 Aug 2023
Led by Redmile Group, Bain Capital Life Sciences; with RA Capital, Samsara BioCapital, Sanofi Ventures, New Leaf Venture Partners, Pontifax Venture Capital, Tekla Capital Management, LLC, BlackRock, Mass General Brigham Ventures, Eurofarma, Soleus Capital.
Sources: abcuro.com, htworld.co.uk, pharmaceuticalmanufacturer.media and 2 more
$155M
Series A 7 Jan 2021
Led by Mass General Brigham Ventures, Sanofi Ventures; with Pontifax Venture Capital, Hongsen Investment Group, RA Capital, Samsara BioCapital.
Sources: abcuro.com, fiercebiotech.com, nutter.com and 3 more
$42M

Abcuro investors

19 investors have backed Abcuro; Mass General Brigham Ventures, Sanofi Ventures and Bain Capital Life Sciences and 3 more led at least one round.

Mass General Brigham Ventures lead, 3 rounds
Sanofi Ventures lead, 3 rounds
Bain Capital Life Sciences lead, 2 rounds
New Enterprise Associates lead, 2 rounds
Redmile Group lead, 2 rounds
Samsara BioCapital 3 rounds
Soleus Capital 2 rounds
abrdn Inc.
BlackRock
Eurofarma
Eurofarma Ventures
Hongsen Investment Group
Tekla Capital Management, LLC

What Abcuro does

Abcuro works in pharmaceutical products, with 13 recorded offerings and customers in biotechnology, healthcare and pharmaceuticals.

Abcuro, Inc. is a United States biotechnology company engaged in the development of precision targeting therapies for autoimmune diseases and cancer. The company focuses on modulating cytotoxic T and natural killer cells that express the KLRG1 marker, with activities including the design and clinical evaluation of monoclonal antibodies for the selective depletion or reactivation of these cells. Abcuro also manages supply chain and quality control operations to support the production of therapeutic products.

Description from Veridion's company data.

Products and services

Biopharmaceutical Research and Development
Precision Targeting Therapy Development
Autoimmune Disease Therapeutic Development
Cancer Therapeutic Development
Monoclonal Antibody Engineering and Production
Cytotoxic T Cell Depletion Therapy Development
Cytotoxic T Cell Reactivation Therapy Development
Clinical Trial Advancement Services
Regulatory Approval Consulting and Services
Therapeutic Product Manufacturing
Therapeutic Product Quality Control
Orphan Drug Designation Advancement
Immunotherapy Innovation Services

Markets

Biotechnology
Healthcare
Pharmaceuticals

Technology

Monoclonal Antibody Therapeutics for KLRG1-Expressing T Cells
Precision Targeting Therapies for Autoimmune Diseases and Cancer
Cytotoxic T Cell Depletion Therapies
Cytotoxic T Cell Reactivation Therapies

Certifications

FDA certified

Business model

Business-to-Business
Manufacturing

Industry codes (NAICS)

325412 Pharmaceutical Preparation Manufacturing 100% match

Questions about Abcuro

What is Abcuro worth?

Valuation $826M (range $542M to $1.3B), as of 24 Oct 2026.

Has Abcuro raised money?

Abcuro has 4 funding rounds on record, from Jan 2021 to Aug 2026, $463M in total. None disclosed a valuation.

Who has invested in Abcuro?

Mass General Brigham Ventures, Sanofi Ventures, Bain Capital Life Sciences, New Enterprise Associates, New Leaf Venture Partners and Redmile Group, and 13 more. Lead investors include Mass General Brigham Ventures, Sanofi Ventures, Bain Capital Life Sciences and New Enterprise Associates.

How many people work at Abcuro?

About 36, down 33% over the last year. Headcount rose from 6 in Jan 2021 to 56 in Mar 2026, then fell to 36 in Sep 2026.

What does Abcuro do?

Abcuro works in pharmaceutical products, with 13 recorded offerings and customers in biotechnology, healthcare and pharmaceuticals. Its main offerings are biopharmaceutical research and development, precision targeting therapy development and autoimmune disease therapeutic development.

When was Abcuro founded, and where is it based?

Abcuro was founded in 2015 and is based in Newton, United States. It has about 36 employees, down 33% over the last year.

How we value companies Report an issue